Nonsteroidal anti-inflammatory drug and aspirin use in relation to lung cancer risk among postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 5, 2015, Pages 790-797

  Baik, Christina S ^a   Brasky, Theodore M ^b   Pettinger, Mary ^c   Luo, Juhua ^d   Gong, Zhihong ^e   Wactawski Wende, Jean ^f   Prentice, Ross L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d INDIANA UNIVERSITY   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CELECOXIB; ESTROGEN; GESTAGEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SALICYLIC ACID DERIVATIVE; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMALL CELL LUNG CANCER; SMOKING; SPINDLE CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; TISSUE SECTION; UNITED STATES; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84982278631     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1322     Document Type: Article

References (31)

1. Bosetti C, Rosato V, Gallus S, Cuzick J, LaVecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012;23:1403-15.
2. Cuzick J, Otto F, Baron J, Brown P, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
3. Horn L, Backlund M, Johnson D. Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin Ther Targets 2009;13:675-88.
4. Lin M, Lee R, Yang P, Ho F, Kuo M. Cyclooxygenase-2 inducing Mcl-1 dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-9002.
5. Saini R, Sanyal S. Chemopreventive effect of nonsteroidal anti-inflammatory drugs on 9, 10-dimethylbenz (a) anthracene-induced lung carcinogenesis in mice. Oncol Res 2009;17:505-18.
6. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-10.
7. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
8. Slatore C, Au D, Littman A, Satia J, White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009;18:1203-7.
9. Hayes J, Anderson K, Folsom A. Association between nonsteroidal antiinflammatory drug use and the incidence of lung cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2006;15:'2226-31.
10. Holick C, Michaud D, Leitzmann M, Willett W, Giovannucci E. Aspirin and lung cancer in men. Br J Cancer 2003;89:1705-8.
11. Ratnasinghe L, Graubard B, Kahle L, Tangrea J, Taylor P, Hawk E. Aspirin use and mortality from cancer in a prospective study. Anticancer Res 2004;24:3177-84.
12. Jacobs E, Thun M, Bain E, Rodriguez C, Henley S, Calle E. A large cohort study of long term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
13. Feskanich D, Bain C, Chan A, Pandeya N, Speizer F, Colditz G. Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br J Cancer 2007;97:1295-99.
14. Stabile L, Gaither A, Gubish C, Hopkins T, Luketich J, et al. Human nonsmall cell lung tumors and cells derived from normal lung express both estrogen receptor a and b and show biological responses to estrogen. Cancer Res 2002;62:2141-50.
15. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, et al. Progesterone receptor in non-small cell lung cancer - A potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005;65:6450-8.
16. Chlebowski R, Schwartz A, Wakelee H, Anderson G, Stefanick M, Manson J, et al. Oestrogen plus progestin in lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51.
17. Brasky T, Liu J, White E, Peters U, Potter J, Walter R, et al. Non-steroidal antiinflammatory drugs and cancer risk in women: results from the Women's Health Initiative. Int J Cancer 2014;135:1869-83.
18. Chlebowski R, Manson J, Anderson G, Cauley J, Aragaki A, Stefanick M, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013;105:526-35.
19. Langer R, White E, Lewis C, Kotchen J, Hendrix S, Trevisan M. The Women's Health Initiative Observational Study: Baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13:S107-S21.
20. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
21. Anderson G, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-S17.
22. Curb J, McTiernan A, Heckbert S, Kooperberg C, Stanford J, Nevitt M, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13:S122-S8.
23. Cook N, Lee I-M, Gaziano J, Gordon D, Ridker P, Manson J, et al. Lowdose aspirin in the primary prevention of cancer. JAMA 2005;294:47-55.
24. Cook N, Lee I-M, Zhang S, Moorthy V, Buring J. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow up of arandomized trial. Ann Intern Med 2013;159:77-85.
25. Rothwell P, Fowkes F, Belch J, Ogawa H, Warlow C, Meade T. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
26. Li T, Kung H, Mack PG, Gandara DR. Genotyping and genomic profiling of non-small cell lung cancer: Implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
27. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013;309:2563-71.
28. Wagner E, Nebreda A. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
29. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-6.
30. Gates M, Tworoger S, Eliassen H, Missmer S, Hankinson S. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:1033-41.
31. Subbaramaiah K, Morris P, Zhou X, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.